fr   en
Agreements
Select a partner :
Type of agreement :





Select a compound/Disease :
Choose date:
[<<]      «      55   |   56   |   57   |   58   |   59   |   60   |   61   |   62   |   63   |   64   |   65      »      [65]
Date Partners Compound / Disease area / Development phase Type of agreement Nature / Financial terms
2006-11-17 Lonza (Switzerland)/Altus Pharmaceuticals (USA)
 
ALTU-135 (TheraCLEC®-Total / orally administered enzyme substitution treatment) / pancreatic insufficiency associated notably with cystic fibrosis, pancreatic cancer and AIDS manufacturing
See details
2006-11-09 Innate Pharma (France)/Clinical Data (USA)
 
predictive test for the treatment response to rituximab (Rituxan®/Mabthera from Genentech/Biogen Idec and Roche) /   licensing
See details
2006-11-08 Biovitrum (Sweden)/Resistentia Pharmaceuticals (Sweden)
 
RES 08 (recombinant fusion protein which blocks the effects of IgE) / allergies and asthma manufacturing
See details
2006-11-08 Lonza (Switzerland)/Genentech (USA)
 
  /   manufacturing
See details
2006-11-06 Kinaxo (Germany)
UCB (Belgium)
KinaTor® technology for drug development R&D
other
See details
2006-10-28 Libragen (France)
Sanofi-Aventis (France)
active molecules discovered in non-culturable micro-organisms / cancer, infectious disease R&D
See details
2006-10-23 GenOdyssee (France)
Baxter (USA)
clotting factors / haemophilia R&D
See details
2006-10-18 Regeneron Pharmaceuticals (USA)
Bayer Healthcare (Germany)
VEGF (vascular endothelium growth factor) Trap-eye / ocular diseases including the neovascular form of aged-related macular degeneration and the pathologies associated with diabetes commercialization/ distribution
development
See details
2006-10-17 Intermune (USA)
Roche (Switzerland)
inhibitors of hepatitis C virus protease / hepatitis C R&D
commercialization/ distribution
See details
2006-10-17 Glenmark Pharmaceuticals (India)
Merck KGaA (Germany)
GRC 8200 (a dipeptidylpeptidase-4 (DPP-4) inhibitor) / type 2 diabetes commercialization/ distribution
development
See details
2006-10-16 Newron Pharmaceuticals (Italy)/Serono (Switzerland)
 
safinamide / Parkinson's disease, Alzheimer's disease and cognitive disorders including restless legs syndrome R&D
manufacturing
commercialization/ distribution
See details
2006-10-02 Biogen Idec (USA)
UCB (Belgium)
CDP 323 / remitting multiple sclerosis commercialization/ distribution
development
See details
2006-09-26 Protalix Biotherapeutics (Israel)
Teva Pharmaceuticals (Israel)
two undisclosed therapeutic proteins / not disclosed. Teva has nevertheless stated that these products address major markets. R&D
licensing
See details
2006-09-20 Procognia (UK)
Teva Pharmaceutical (Israel)
two undisclosed biopharmaceutical products / not disclosed other
See details
2006-09-19 Exonhit Therapeutics (France)
Allergan (USA)
Undisclosed compounds / neurodegenerative diseases, including Parkinson's disease and Alzheimer's disease, pain and ophthalmology R&D
commercialization/ distribution
See details
[<<]      «      55   |   56   |   57   |   58   |   59   |   60   |   61   |   62   |   63   |   64   |   65      »      [65]